Future of the Psilocybin Market (2026-2035): Clinical Research, Therapeutic Applications & Global Market Growth

Psilocybin Market size was USD $6.78 Billion in 2025, expected to reach USD $6.78 Billion by 2035, and growing at a CAGR of 10.90% during the forecast period 2026-2035.

DataM Intelligence has released its latest "Psilocybin Market Size 2026" report, delivering comprehensive insights into market trends, growth opportunities, competitive dynamics, and regional performance. The report covers market size by value and volume, CAGR forecasts, and emerging opportunities, the report delivers data-driven insights into industry developments, competitive trends, and future market outlook, enabling more effective strategic planning and market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/psilocybin-market?kb

United States: Recent Industry Developments

✅ July 2026: Compass Pathways reported six-month Phase 3 data for COMP360, showing sustained benefits in treatment-resistant depression and continued progress toward a potential U.S. regulatory submission.

✅ May 2026: A Sheppard Pratt clinical study published findings indicating that a single 25 mg dose of COMP360, combined with psychological support, was associated with rapid and sustained reductions in suicidal ideation among patients with treatment-resistant depression.

✅ April 2026: The U.S. FDA granted Compass Pathways a rolling NDA review and awarded COMP360 a Commissioner's National Priority Voucher for treatment-resistant depression, accelerating its regulatory pathway.

✅ February 2026: Compass Pathways announced positive Phase 3 COMP006 results, with two 25 mg doses of COMP360 producing a statistically significant reduction in depressive symptoms compared with the 1 mg control.

Find the right strategic partners to accelerate your business. Get started today:- https://www.datamintelligence.com/partner-identification-enquiry/psilocybin-market?kb

Top List of Key Player:

Compass Pathways, Cybin Inc., AtaiBeckley, MindMed, Usona Institute, GH Research, Filament Health, Psyence Biomedical, Numinus Wellness and Silo Pharma.

Key Industry Developments 2026:

✅ July 2026: Compass Pathways reported 26-week results from its Phase 3 COMP006 trial of COMP360, its proprietary synthetic psilocybin formulation for treatment-resistant depression, with the findings supporting a durable treatment response profile.

✅ June 2026: Optimi Health expanded its pharmaceutical-grade psilocybin portfolio by launching standardized 1 mg and 2 mg microdose products for authorized clinical research organizations and completed its first export of naturally derived psilocybin to the United Kingdom for a planned Phase 2 clinical trial.

✅ May 2026: Red Light Holland highlighted peer-reviewed clinical findings showing that a single dose of psilocybin reduced cocaaine use over six months, while its subsidiary Filament Health holds exclusive rights to the related trial data and intellectual property and is advancing PEX010 as a botanical psilocybin candidate.

✅ April 2026: Psyence BioMed initiated patient dosing in its Phase IIb trial evaluating NPX-5, a GMP-compliant, nature-derived psilocybin candidate, for adjustment disorder in patients with cancer receiving palliative care.

✅ March 2026: Red Light Holland and Filament Health expanded the clinical research network for PEX010 through new license agreements with institutions in Australia, the U.K., and Canada, alongside research shipments supporting multiple psilocybin studies.

✅ February 2026: Compass Pathways announced positive Phase 3 COMP006 results for COMP360 in treatment-resistant depression, reporting a statistically significant improvement in symptom severity and subsequently progressing toward FDA rolling review.

✅ January 2026: Compass Pathways advanced its COMP360 development strategy, highlighting its Phase 3 program in treatment-resistant depression and planned clinical development in PTSD, while AtaiBeckley outlined its 2026 pipeline strategy following its combination with Beckley Psytech.

How Our Market Research Process Works 2026-2035:

The Psilocybin Market report by DataM Intelligence delivers comprehensive insights backed by extensive primary and secondary research. It analyzes key market trends, competitive dynamics, regulatory developments, technological advancements, emerging innovations, and growth opportunities while highlighting potential challenges and evolving market conditions. The report provides actionable intelligence to support strategic planning and identify future market potential.

Latest M & A/ partnerships in 2026:

• July 16, 2026: Eli Lilly agreed to acquire AtaiBeckley for up to US$3.8 billion, including US$2.8 billion upfront cash and up to US$1 billion in milestone payments. The transaction expands Lilly's psychedelic medicine pipeline, although AtaiBeckley's lead asset BPL-003 is based on 5-MeO-DMT rather than psilocybin.

• June 30, 2026: XTL Biopharmaceuticals completed its acquisition of 83.4% of Psyga Bio, gaining access to clinical-stage programs, a GMP-ready facility for botanical and synthetic psilocybin manufacturing, and proprietary psilocybin technologies.

• April 29, 2026: Red Light Holland completed the acquisition of 100% of Filament Health, creating a vertically integrated psychedelic platform that includes Filament's PEX010 botanical psilocybin candidate and 76 issued patents across 15 patent families.

• April 29, 2026: XTL Biopharmaceuticals announced a definitive agreement to acquire 100% of Psyga Bio, targeting its psilocybin and psychedelic drug-development pipeline, licensed GMP manufacturing capabilities and mushroom-derived technologies.

• February 20, 2026: Psyence BioMed announced a US$5 million strategic equity investment in PsyLabs through a share-for-share exchange, with PsyLabs expected to receive approximately 49.98% of Psyence BioMed after the transaction. The deal strengthens access to pharmaceutical-grade psychedelic manufacturing and includes psilocybin supply capabilities.

Buy Now & Unlock 360° Complete Market Insights: https://www.datamintelligence.com/buy-now-page?report=psilocybin-market?kb

Japan: Recent Industry Developments

✅ June 2026: Keio University Hospital reported results from Japan's clinical study of psilocybin for treatment-resistant depression. The 12-participant study achieved a 91.7% completion rate, with significant improvements in several depression measures following treatment.

✅ February 2026: Researchers from Keio University published a comprehensive review covering psilocybin's clinical trials, neuroimaging evidence, therapeutic potential and regulatory landscape for psychiatric disorders.

✅ January 2026: Keio University researchers reported progress from Japan's pioneering psilocybin clinical program for treatment-resistant depression, with the study involving 12 participants and reporting only mild and transient adverse events during the trial period.

✅ January 2026: Japan continued its long-term evaluation of psilocybin treatment through a 12-month follow-up study incorporating 7-Tesla MRI assessments through RIKEN's Brain Science Institute to investigate longer-term safety, efficacy and brain-related outcomes.

Key Segmentation Plannings (2026):

By Product Type: Synthetic Psilocybin API and Drug Products, Natural Psilocybin Products, Biosynthetic Psilocybin, Psilocin and Deuterated Analogs, Formulation and Delivery Technologies, Therapy and Integration Services, Digital Monitoring and Training Tools.

By Application: Treatment-Resistant Depression, Major Depressive Disorder, Anxiety Disorders, Substance Use Disorders, PTSD, Palliative Care Distress, Cluster Headache and Other Neurological Conditions, Research and Wellness Supervised Use

By End-User: Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, Hospitals and Academic Medical Centers, Specialty Psychedelic Clinics, Licensed Psilocybin Service Centers, Mental Health Providers, Contract Manufacturers, Research Institutes.

By Source: Synthetic, Natural, Biosynthetic, Semi Synthetic Analogs.

By Route/Delivery Model: Oral Supervised Therapy, Adjunctive Psychotherapy Model, Service Center Administration, Clinical Trial Administration, Digital Supported Hybrid Care.

Global Market Growth Regional Analysis:

⇥ North merica (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1 - Market Overview: Provides a comprehensive introduction to the Psilocybin Market, including key segments by region, product type, and application, along with market size, growth potential, and short- and long-term outlook.

Chapter 2 - Emerging Trends: Highlights the latest industry trends, technological advancements, and innovations driving market transformation.

Chapter 3 - Competitive Landscape: Analyzes the competitive environment, including market share, strategic developments, partnerships, and recent mergers and acquisitions.

Chapter 4 - Leading Company Profiles: Presents detailed profiles of major market participants, covering revenue, product portfolios, operating performance, and recent developments.

Chapters 5 & 6 - Regional and Country Analysis: Delivers in-depth insights into market performance across key regions and countries, highlighting revenue trends, growth opportunities, and market potential.

Chapter 7 - Market Segmentation: Examines the market by type, identifying key segments, growth prospects, and high-opportunity areas.

Chapter 8 - Application Analysis: Explores major application areas, emerging demand trends, and sectors contributing to market expansion.

Chapter 9 - Supply Chain Analysis: Maps the end-to-end industry value chain, providing insights into upstream suppliers, downstream channels, and overall market structure.

Chapter 10 - Key Insights and Strategic Outlook: Summarizes the report with actionable insights, strategic recommendations, and growth opportunities to support future market planning.

Request a Customized Market Report Today:- https://www.datamintelligence.com/customize/psilocybin-market?kb

Japan: Recent Industry Developments

✅ June 2026: Keio University Hospital reported results from Japan's clinical study of psilocybin for treatment-resistant depression. The 12-participant study achieved a 91.7% completion rate, with significant improvements in several depression measures following treatment.

✅ February 2026: Researchers from Keio University published a comprehensive review covering psilocybin's clinical trials, neuroimaging evidence, therapeutic potential and regulatory landscape for psychiatric disorders.

✅ January 2026: Keio University researchers reported progress from Japan's pioneering psilocybin clinical program for treatment-resistant depression, with the study involving 12 participants and reporting only mild and transient adverse events during the trial period.

✅ January 2026: Japan continued its long-term evaluation of psilocybin treatment through a 12-month follow-up study incorporating 7-Tesla MRI assessments through RIKEN's Brain Science Institute to investigate longer-term safety, efficacy and brain-related outcomes.

Market Drivers

• Growing Clinical Evidence: Phase 3 studies and recent clinical research continue to show potential for psilocybin-based treatments in treatment-resistant depression and other mental health conditions.

• Supportive Regulatory Developments: The FDA issued final guidance for psychedelic drug clinical investigations in July 2026, providing clearer direction for companies developing psilocybin therapies.

• Government Funding & Research Programs: U.S. agencies are allocating substantial funding toward psychedelic and behavioral-health research, supporting clinical development and evidence generation.

• Demand for New Mental Health Treatments: Research into psilocybin is gaining attention as healthcare systems seek additional options for conditions such as treatment-resistant depression and PTSD, where existing therapies may provide inadequate relief.

FAQ's

Q1: What is the current market size of the Psilocybin Market and its future outlook?

Ans: The global Psilocybin Market reached USD $6.78 Billion in 2025 and is forecast to attain USD $6.78 Billion by 2035

Q2: How fast is the Psilocybin Market expected to grow during the forecast period?

Ans: The market is projected to expand at a CAGR of 10.90% from 2026 to 2035, reflecting strong growth potential over the forecast period.

Q3: Which region leads the Psilocybin Market?

Ans: North America accounted for the largest market share, contributing 48.60% in 2025

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.